Dust mite-specific immunoglobulin E (HDM-sIgE) (HDM-sIgE)

Dust mite-specific immunoglobulin E (IgE) is a specialized antibody produced by the immune system in response to proteins found in house dust mites, primarily Dermatophagoides pteronyssinus and Dermatophagoides farinae (Source: NIH, National Institute of Allergy and Infectious Diseases). These antibodies play a central role in the pathogenesis of perennial allergic diseases by sensitizing mast cells and basophils through binding to the high-affinity FcεRI receptor. When a sensitized individual is exposed to dust mite allergens, such as Der p 1 or Der f 2, the allergens cross-link the IgE molecules on the cell surface, triggering the immediate release of inflammatory mediators like histamine and leukotrienes (Source: StatPearls, "Type I Hypersensitivity"). This cascade results in airway inflammation, mucus production, and bronchoconstriction, which are characteristic of allergic asthma and rhinitis. Therapeutic strategies targeting this pathway include monoclonal antibodies like Omalizumab, which sequester circulating IgE to prevent receptor binding, and allergen-specific immunotherapy (AIT) designed to induce long-term immune tolerance (Source: FDA, "Odactra Prescribing Information").

Other names

House dust mite-specific IgEDermatophagoides-specific IgEHDM-specific IgEAnti-dust mite IgE

Anti-IgE monoclonal antibodies like Omalizumab bind to the Cε3 domain of circulating IgE, preventing its interaction with high-affinity FcεRI receptors on mast cells and basophils, thereby inhibiting the allergic cascade (Source: PubMed, PMID: 12642831). Allergen-specific immunotherapy (AIT) involves the repeated administration of dust mite allergens to induce immunological tolerance, characterized by an increase in allergen-specific IgG4 antibodies and a reduction in the Th2-mediated inflammatory response (Source: FDA, Odactra Prescribing Information).